PACIFIC BIOSCIENCES OF CALIFORNIA overview

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance PR Newswire MENLO PARK, Calif., April 16, 2024 Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results Preliminary revenue of...

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes PR Newswire MENLO PARK, Calif., March 27, 2024 HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif. , March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate...

PacBio Grants Equity Incentive Award to New Employee PR Newswire MENLO PARK, Calif., March 22, 2024 MENLO PARK, Calif. , March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800...

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions PR Newswire MENLO PARK, Calif., March 12, 2024 HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution...

PacBio to Present at Upcoming Investor Conferences PR Newswire MENLO PARK, Calif., Feb. 26, 2024 MENLO PARK, Calif. , Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 , at 1:30 PM ET in Boston, MA Barclays 26th Annual Global Healthcare Conference on...

PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire MENLO PARK, Calif., Feb. 15, 2024 MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. Fourth quarter results Revenue of $58.4 million , a 113% increase compared with $27.4 million in the prior-year period. Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period....

PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale PR Newswire MENLO PARK, Calif., Feb. 5, 2024 New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System MENLO PARK, Calif. , Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its...

PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024 PR Newswire MENLO PARK, Calif., Jan. 25, 2024 MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024 , at 5:00 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Thursday,...